History of pregnancy and blood transfusion

According to new study, males transfused with blood from a woman with a history of pregnancy appear to be 13 percent more likely to die compared with those who received blood from man. The highest risk seemed to be in men 18 to 50 years old. They had a 50 percent increased risk of death after receiving blood from a previously pregnant female, the risk remained increased for many years after transfusion.

 No such increase was observed for female recipients, or for male recipients over 50 years. Pregnancy might affect a woman's immune system in some way that makes her blood more risky for a man. However, the risk is unlikely to prompt any immediate change in blood donation policies.

The study focused on patients data that received blood transfusions from - men, never-pregnant women and women who'd been pregnant. After receiving a single transfusion, the three-year death rate among men was 13.5 percent for those who received male blood, 13.1 percent for those who got never-pregnant female blood, and nearly 17 percent for those who received blood from a previously pregnant female.

U.S. blood centers sometimes exclude women with a history of pregnancy from donation of blood products like platelets or plasma, due to a condition called transfusion-related acute lung injury (TRALI). TRALI typically occurs within six hours of a transfusion, and between 5 to 25 percent of patients who develop the condition die from it, according to the U.S. National Heart, Lung, and Blood Institute.

TRALI is thought to be caused by antibodies that women develop through exposure to fetal blood during pregnancy. It has been associated specifically with previously pregnant female donors, the researchers said.
However, those antibodies aren't what caused the death risk found in this new study, which stretches out for years.

Pregnancy might make a lasting change to the immune system of a woman, because she has to tolerate a foreign object in her body for nine months,
There is a lot of immune regulation involved in making a pregnancy possible, some of this suppressive regulation could last long after the pregnancy.
          haleplushearty.blogspot.com

Mylotarg for treating acute myeloid leukemia

Mylotarg (gemtuzumab ozogamicin) has been approved for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).

AML is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of white blood cells in the bloodstream.

Mylotarg is a targeted therapy that consists of an antibody connected to an anti-tumor agent that is toxic to cells. It is thought to work by taking the anti-tumor agent to the AML cells that express the CD33 antigen, blocking the growth of cancerous cells and causing cell death.

Common side effects of Mylotarg are fever, nausea, infection, vomiting, bleeding, low levels of platelets in the blood, swelling and sores in the mouth, constipation, rash, headache, liver damage, and low levels of certain white blood cells.
          haleplushearty.blogspot.com      

Duzallo drugs for treating gout

Duzallo is a prescription medicine that contains two medicines, a URAT1 inhibitor called lesinurad and a xanthine oxidase inhibitor called allopurinol. It is used to lower uric acid levels in the blood of people with gout.

Active ingredients are lesinurad and allopurinol. Inactive ingredients: crospovidone, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, iron oxide red, iron oxide yellow, titanium dioxide, and triacetin.

Duzallo can cause serious side effects, like kidney problems. People taking Duzallo may have kidney problems such as a sudden decrease in kidney function (acute kidney failure).
Duzallo can affect bone marrow and cause low red blood cells, white blood cells and platelets.

Other side effects are: skin rash; blistering of the skin, mouth, nose, and genitals, painful red or purple skin that looks burned and peels off, joint pain; swollen glands red, painful, watery eyes; persistent itching; hives, fever, loss of appetite, weight loss, fatigue, nausea, heartburn and diarrhea
          haleplushearty.blogspot.com

Besponsa for treatment of acute lymphoblastic leukemia

Food and Drug Administration approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. ALL.

B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.

Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.

Women who are pregnant or breastfeeding should not take Besponsa because it may cause harm to a developing fetus or a newborn baby.

Side effects of Besponsa include low levels of platelets, low levels of certain white blood cells, infection, low levels of red blood cells, fatigue, severe bleeding, fever, nausea, headache, low levels of white blood cells with fever, liver damage, abdominal pain, high levels of bilirubin in the blood,
decrease in blood cell and platelet production, infusion-related reactions and problems with the heart’s electrical pulses.
          haleplushearty.blogspot.com